Managing Waldenström's macroglobulinemia with BTK inhibitors

Bruton's tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenström's macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT). It offers deep and durable responses with a manageable safety pro...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Leukemia Ročník 37; číslo 1; s. 35 - 46
Hlavní autoři:	Buske, Christian, Jurczak, Wojciech, Salem, Joe-Elie, Dimopoulos, Meletios A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.01.2023
Témata:	Agammaglobulinaemia Tyrosine Kinase Atrial Fibrillation - chemically induced Atrial Fibrillation - drug therapy Bruton's tyrosine kinase Cardiovascular diseases Chemotherapy Clinical trials Covalence CXCR4 protein Effectiveness Health risks Humans Immunotherapy Inhibitor drugs Kinases Macroglobulinemia Mutation MyD88 protein Myeloid Differentiation Factor 88 - genetics Neoplasm Recurrence, Local - drug therapy Patients Protein Kinase Inhibitors - pharmacology Protein-tyrosine kinase Risk management Safety management Selectivity Side effects Signal Transduction Toxicity Tyrosine Waldenstrom Macroglobulinemia - drug therapy Waldenstrom Macroglobulinemia - genetics
ISSN:	0887-6924, 1476-5551, 1476-5551
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!